Regulation of inflammatory responses by neuregulin-1 in brain ischemia and microglial cells in vitro involves the NF-kappa B pathway

Journal of Neuroinflammation

Volumn 13, Issue 1, 2016, Pages

  Simmons, Lauren J ^a   Surles Zeigler, Monique C ^a   Li, Yonggang ^b   Ford, Gregory D ^c   Newman, Gale D ^a   Ford, Byron D ^b  

^a MOREHOUSE SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c GEORGIA HIGHLANDS COLLEGE   (United States)

Author keywords

Bioinformatics; Gene expression; Inflammation; Ischemia; Microarray; Neuregulin; Stroke; Transcription factor binding site (TFBS)

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; NEU DIFFERENTIATION FACTOR; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR RELA; TRANSCRIPTION FACTOR RELB; TUMOR NECROSIS FACTOR; CYTOKINE; I KAPPA B; LIPOPOLYSACCHARIDE; MESSENGER RNA;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BINDING SITE; BIOINFORMATICS; BRAIN ISCHEMIA; BRAIN TISSUE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; IN VITRO STUDY; INTRACELLULAR SIGNALING; INTRACELLULAR TRANSPORT; MALE; MICROGLIA; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN; PREDICTION; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RAT; TISSUE MICROARRAY; TRANSCRIPTION REGULATION; WESTERN BLOTTING; ANIMAL; BIOLOGY; CEREBRAL ARTERY DISEASE; COMPLICATION; DRUG EFFECTS; ENCEPHALITIS; METABOLISM; MICROARRAY ANALYSIS; PATHOLOGY; SPRAGUE DAWLEY RAT; TRANSFORMED CELL LINE;

ANIMALS; CELL LINE, TRANSFORMED; COMPUTATIONAL BIOLOGY; CYTOKINES; ENCEPHALITIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GRANULOCYTE COLONY-STIMULATING FACTOR; I-KAPPA B PROTEINS; INFARCTION, MIDDLE CEREBRAL ARTERY; LIPOPOLYSACCHARIDES; MALE; MICROARRAY ANALYSIS; MICROGLIA; NEUREGULIN-1; NF-KAPPA B; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER;

EID: 84984986869     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/s12974-016-0703-7     Document Type: Article

References (64)

1. Li Y, et al. Neuroprotection by neuregulin-1 in a rat model of permanent focal cerebral ischemia. Brain Res. 2007;1184:277-83.
2. Xu Z, et al. Extended therapeutic window and functional recovery after intraarterial administration of neuregulin-1 after focal ischemic stroke. J Cereb Blood Flow Metab. 2006;26(4):527-35.
3. Xu Z, et al. Neuroprotection by neuregulin-1 following focal stroke is associated with the attenuation of ischemia-induced pro-inflammatory and stress gene expression. Neurobiol Dis. 2005;19(3):461-70.
4. Iaci JF, et al. Glial growth factor 2 promotes functional recovery with treatment initiated up to 7 days after permanent focal ischemic stroke. Neuropharmacology. 2010;59(7-8):640-9.
5. Guo WP, et al. Neuroprotective effects of neuregulin-1 in rat models of focal cerebral ischemia. Brain Res. 2006;1087(1):180-5.
6. Shyu WC, et al. Neuregulin-1 reduces ischemia-induced brain damage in rats. Neurobiol Aging. 2004;25(7):935-44.
7. Xu Z, et al. Neuregulin-1 is neuroprotective and attenuates inflammatory responses induced by ischemic stroke. Biochem Biophys Res Commun. 2004;322(2):440-6.
8. Li Q, et al. Effect of neuregulin on apoptosis and expressions of STAT3 and GFAP in rats following cerebral ischemic reperfusion. J Mol Neurosci. 2009;37(1):67-73.
9. Solomon W, et al. Neuregulin-1 attenuates mortality associated with experimental cerebral malaria. J Neuroinflammation. 2014;11:9.
10. Li Y, et al. Neuregulin-1 inhibits neuroinflammatory responses in a rat model of organophosphate-nerve agent-induced delayed neuronal injury. J Neuroinflammation. 2015;12:64.
11. Dimayuga FO, et al. The neuregulin GGF2 attenuates free radical release from activated microglial cells. J Neuroimmunol. 2003;136(1-2):67-74.
12. Touzani O, Roussel S, MacKenzie ET. The ischaemic penumbra. Curr Opin Neurol. 2001;14(1):83-8.
13. Dirnagl U, Iadecola C, Moskowitz MA. Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci. 1999;22(9):391-7.
14. Rogove AD, Lu W, Tsirka SE. Microglial activation and recruitment, but not proliferation, suffice to mediate neurodegeneration. Cell Death Differ. 2002;9(8):801-6.
15. Graeber MB, Streit WJ. Microglia: biology and pathology. Acta Neuropathol. 2010;119(1):89-105.
16. McKimmie CS, et al. Innate immune response gene expression profiles of N9 microglia are pathogen-type specific. J Neuroimmunol. 2006;175(1-2):128-41.
17. Jin R, Yang G, Li G. Inflammatory mechanisms in ischemic stroke: role of inflammatory cells. J Leukoc Biol. 2010;87(5):779-89.
18. Fernandes A, Miller-Fleming L, Pais TF. Microglia and inflammation: conspiracy, controversy or control? Cell Mol Life Sci. 2014;71(20):3969-85.
19. Graeber MB, Li W, Rodriguez ML. Role of microglia in CNS inflammation. FEBS Lett. 2011;585(23):3798-805.
20. Nathan C, Ding A. Nonresolving inflammation. Cell. 2010;140(6):871-82.
21. Widgerow AD. Cellular resolution of inflammation-catabasis. Wound Repair Regen. 2012;20(1):2-7.
22. Nurmi A, et al. Nuclear factor-kappaB contributes to infarction after permanent focal ischemia. Stroke. 2004;35(4):987-91.
23. Hayden MS, Ghosh S. Shared principles in NF-kappaB signaling. Cell. 2008;132(3):344-62.
24. Ridder DA, Schwaninger M. NF-kappaB signaling in cerebral ischemia. Neuroscience. 2009;158(3):995-1006.
25. Chen CC, et al. Protein kinase C eta mediates lipopolysaccharide-induced nitric-oxide synthase expression in primary astrocytes. J Biol Chem. 1998;273(31):19424-30.
26. Boulet I, et al. Lipopolysaccharide- and interferon-gamma-induced expression of hck and lyn tyrosine kinases in murine bone marrow-derived macrophages. Oncogene. 1992;7(4):703-10.
27. Ko HM, et al. Inflexin attenuates proinflammatory responses and nuclear factor-kappaB activation in LPS-treated microglia. Eur J Pharmacol. 2010;633(1-3):98-106.
28. Jin H, et al. Myrislignan attenuates lipopolysaccharide-induced inflammation reaction in murine macrophage cells through inhibition of NF-kappaB signalling pathway activation. Phytother Res. 2012;26(9):1320-6.
29. Wang X, et al. Gomisin A inhibits lipopolysaccharide-induced inflammatory responses in N9 microglia via blocking the NF-kappaB/MAPKs pathway. Food Chem Toxicol. 2014;63:119-27.
30. Sun SC. Non-canonical NF-kappaB signaling pathway. Cell Res. 2011;21(1):71-85.
31. Lawrence T, et al. IKKalpha limits macrophage NF-kappaB activation and contributes to the resolution of inflammation. Nature. 2005;434(7037):1138-43.
32. Bonizzi G, Karin M. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol. 2004;25(6):280-8.
33. Xiao G, et al. Alternative pathways of NF-kappaB activation: a double-edged sword in health and disease. Cytokine Growth Factor Rev. 2006;17(4):281-93.
34. Xiao G, Harhaj EW, Sun SC. NF-kappaB-inducing kinase regulates the processing of NF-kappaB2 p100. Mol Cell. 2001;7(2):401-9.
35. Lawrence T. The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harb Perspect Biol. 2009;1(6):a001651.
36. Marienfeld R, et al. RelB forms transcriptionally inactive complexes with RelA/p65. J Biol Chem. 2003;278(22):19852-60.
37. Lwin T, et al. Bone marrow stromal cells prevent apoptosis of lymphoma cells by upregulation of anti-apoptotic proteins associated with activation of NF-kappaB (RelB/p52) in non-Hodgkin's lymphoma cells. Leukemia. 2007;21(7):1521-31.
38. Zong WX, et al. The prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcriptional target of NF-kappaB that blocks TNFalpha-induced apoptosis. Genes Dev. 1999;13(4):382-7.
39. Xia Y, et al. RelB regulation of chemokine expression modulates local inflammation. Am J Pathol. 1997;151(2):375-87.
40. Limpert AS, Carter BD. Axonal neuregulin 1 type III activates NF-kappaB in Schwann cells during myelin formation. J Biol Chem. 2010;285(22):16614-22.
41. Hinohara K, et al. ErbB receptor tyrosine kinase/NF-kappaB signaling controls mammosphere formation in human breast cancer. Proc Natl Acad Sci U S A. 2012;109(17):6584-9.
42. Limpert AS, et al. NF-kappaB forms a complex with the chromatin remodeler BRG1 to regulate Schwann cell differentiation. J Neurosci. 2013;33(6):2388-97.
43. Frensing T, Kaltschmidt C, Schmitt-John T. Characterization of a neuregulin-1 gene promoter: positive regulation of type I isoforms by NF-kappaB. Biochim Biophys Acta. 2008;1779(2):139-44.
44. Han ME, et al. Overexpression of NRG1 promotes progression of gastric cancer by regulating the self-renewal of cancer stem cells. J Gastroenterol. 2015;50(6):645-56.
45. Bhat-Nakshatri P, Sweeney CJ, Nakshatri H. Identification of signal transduction pathways involved in constitutive NF-kappaB activation in breast cancer cells. Oncogene. 2002;21(13):2066-78.
46. Chen D, et al. NIK is a component of the EGF/heregulin receptor signaling complexes. Oncogene. 2003;22(28):4348-55.
47. Karanam S, Moreno CS. CONFAC: automated application of comparative genomic promoter analysis to DNA microarray datasets. Nucleic Acids Res. 2004;32(Web Server issue):W475-84.
48. Pulliam JV, et al. Computational identification of conserved transcription factor binding sites upstream of genes induced in rat brain by transient focal ischemic stroke. Brain Res. 2013;1495:76-85.
49. Ford G, et al. Expression Analysis Systematic Explorer (EASE) analysis reveals differential gene expression in permanent and transient focal stroke rat models. Brain Res. 2006;1071(1):226-36.
50. Harari OA, Liao JK. NF-kappaB and innate immunity in ischemic stroke. Ann N Y Acad Sci. 2010;1207:32-40.
51. Acosta SA, et al. Combination therapy of human umbilical cord blood cells and granulocyte colony stimulating factor reduces histopathological and motor impairments in an experimental model of chronic traumatic brain injury. PLoS One. 2014;9(3):e90953.
52. Shin YK, Cho SR. Exploring erythropoietin and G-CSF combination therapy in chronic stroke patients. Int J Mol Sci. 2016;17:4.
53. Sikoglu EM, et al. Enhancement in cognitive function recovery by granulocyte-colony stimulating factor in a rodent model of traumatic brain injury. Behav Brain Res. 2014;259:354-6.
54. Chen C, Edelstein LC, Gelinas C. The Rel/NF-kappaB family directly activates expression of the apoptosis inhibitor Bcl-x(L). Mol Cell Biol. 2000;20(8):2687-95.
55. Yoza BK, et al. Induction of RelB participates in endotoxin tolerance. J Immunol. 2006;177(6):4080-5.
56. Hayden MS, Ghosh S. Signaling to NF-kappaB. Genes Dev. 2004;18(18):2195-224.
57. Guan YF, et al. Neuregulin 1 protects against ischemic brain injury via ErbB4 receptors by increasing GABAergic transmission. Neuroscience. 2015;307:151-9.
58. Fontaine RH, et al. IL-9/IL-9 receptor signaling selectively protects cortical neurons against developmental apoptosis. Cell Death Differ. 2008;15(10):1542-52.
59. Guo Y, et al. Granulocyte colony-stimulating factor improves alternative activation of microglia under microenvironment of spinal cord injury. Neuroscience. 2013;238:1-10.
60. Yamasaki R, et al. Restoration of microglial function by granulocyte-colony stimulating factor in ALS model mice. J Neuroimmunol. 2010;229(1-2):51-62.
61. Richard M, et al. Interleukin-9 regulates NF-kappaB activity through BCL3 gene induction. Blood. 1999;93(12):4318-27.
62. Bundy DL, McKeithan TW. Diverse effects of BCL3 phosphorylation on its modulation of NF-kappaB p52 homodimer binding to DNA. J Biol Chem. 1997;272(52):33132-9.
63. Gao R, et al. A phase II, randomized, double-blind, multicenter, based on standard therapy, placebo-controlled study of the efficacy and safety of recombinant human neuregulin-1 in patients with chronic heart failure. J Am Coll Cardiol. 2010;55(18):1907-14.
64. Jabbour A, et al. Parenteral administration of recombinant human neuregulin-1 to patients with stable chronic heart failure produces favourable acute and chronic haemodynamic responses. Eur J Heart Fail. 2011;13(1):83-92.